[
  {
    "ts": "2025-11-06T08:04:00+00:00",
    "headline": "Novo Nordisk CFO outlines ‘ultimate defense’ against stock downgrades and lawsuits to retain weight-loss crown",
    "summary": "\"The ultimate defence in our industry is in innovation,\" Knudsen told Fortune in an exclusive interview.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
    "source": "Fortune",
    "provider": "yfinance",
    "raw": {
      "id": "5848522d-6379-3c44-88b1-55d6477f7e91",
      "content": {
        "id": "5848522d-6379-3c44-88b1-55d6477f7e91",
        "contentType": "STORY",
        "title": "Novo Nordisk CFO outlines ‘ultimate defense’ against stock downgrades and lawsuits to retain weight-loss crown",
        "description": "",
        "summary": "\"The ultimate defence in our industry is in innovation,\" Knudsen told Fortune in an exclusive interview.",
        "pubDate": "2025-11-06T08:04:00Z",
        "displayTime": "2025-11-06T08:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4",
          "originalWidth": 2048,
          "originalHeight": 1365,
          "caption": "Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M_qy5Z_He6HZ19cMidPX0w--~B/aD0xMzY1O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4.cf.webp",
              "width": 2048,
              "height": 1365,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JRApwcThX.P.KPvduaht_Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Fortune",
          "url": "http://fortune.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T10:47:09+00:00",
    "headline": "Impressive Earnings May Not Tell The Whole Story For Eli Lilly (NYSE:LLY)",
    "summary": "Unsurprisingly, Eli Lilly and Company's ( NYSE:LLY ) stock price was strong on the back of its healthy earnings report...",
    "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b849e098-f319-3b50-b156-6496ffe1509d",
      "content": {
        "id": "b849e098-f319-3b50-b156-6496ffe1509d",
        "contentType": "STORY",
        "title": "Impressive Earnings May Not Tell The Whole Story For Eli Lilly (NYSE:LLY)",
        "description": "",
        "summary": "Unsurprisingly, Eli Lilly and Company's ( NYSE:LLY ) stock price was strong on the back of its healthy earnings report...",
        "pubDate": "2025-11-06T10:47:09Z",
        "displayTime": "2025-11-06T10:47:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:58:55+00:00",
    "headline": "Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift",
    "summary": "Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.",
    "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "da465711-34fe-3aef-ba8a-0193b69d9344",
      "content": {
        "id": "da465711-34fe-3aef-ba8a-0193b69d9344",
        "contentType": "STORY",
        "title": "Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift",
        "description": "",
        "summary": "Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.",
        "pubDate": "2025-11-06T12:58:55Z",
        "displayTime": "2025-11-06T12:58:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T11:45:00+00:00",
    "headline": "Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using th",
    "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "57994221-aaeb-3d62-b328-698a7835bfe5",
      "content": {
        "id": "57994221-aaeb-3d62-b328-698a7835bfe5",
        "contentType": "STORY",
        "title": "Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using th",
        "pubDate": "2025-11-06T11:45:00Z",
        "displayTime": "2025-11-06T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T15:23:00+00:00",
    "headline": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
    "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
    "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
      "content": {
        "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
        "contentType": "STORY",
        "title": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
        "description": "",
        "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
        "pubDate": "2025-11-06T15:23:00Z",
        "displayTime": "2025-11-06T15:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:06:47+00:00",
    "headline": "Novo Nordisk again raises bid in battle for obesity start-up Metsera",
    "summary": "Novo Nordisk has once again sweetened its offer for obesity biotech Metsera, as the Ozempic maker trades back-and-forth bids with Pfizer in a...",
    "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
      "content": {
        "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
        "contentType": "STORY",
        "title": "Novo Nordisk again raises bid in battle for obesity start-up Metsera",
        "description": "",
        "summary": "Novo Nordisk has once again sweetened its offer for obesity biotech Metsera, as the Ozempic maker trades back-and-forth bids with Pfizer in a...",
        "pubDate": "2025-11-06T16:06:47Z",
        "displayTime": "2025-11-06T16:06:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:05:39+00:00",
    "headline": "Lilly, Novo to Lower Obesity Drug Prices in Deal With Trump",
    "summary": "The deals with Lilly and Novo, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to certain people on Medicare, the government health plan for older Americans, according to senior administration officials.  The companies’ products will receive a three-year grace period from Trump’s forthcoming duties on pharmaceutical imports, an official said, similar terms to those clinched by their rivals in previous drug-price deals.",
    "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
      "content": {
        "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
        "contentType": "STORY",
        "title": "Lilly, Novo to Lower Obesity Drug Prices in Deal With Trump",
        "description": "",
        "summary": "The deals with Lilly and Novo, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to certain people on Medicare, the government health plan for older Americans, according to senior administration officials.  The companies’ products will receive a three-year grace period from Trump’s forthcoming duties on pharmaceutical imports, an official said, similar terms to those clinched by their rivals in previous drug-price deals.",
        "pubDate": "2025-11-06T17:05:39Z",
        "displayTime": "2025-11-06T17:05:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gCZCsUJlU_eGSKICIOeYWw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WHyHD1H6zLz3nNV.CBM0Ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "MRK.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]